TriangleNCT00565851 · OUTCOME
Progression-free Survival (Chemotherapy Analysis)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Radiographic assessment of disease was conducted during chemotherapy and then every 6 months during the maintenance / surveillance phase
What was measured
Progression-free survival was defined as the time from randomization to cancer progression as shown on radiography, according to the RECIST version 1.0 criteria, an increase in the CA125 level according to Gynecologic Cancer InterGroup (GCIG) criteria, global deterioration of health, or death from any cause.
Analysis population: All patients who were enrolled and eligible for the chemotherapy analysis (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).
Groups in this outcome
Paclitaxel and Carboplatin Chemotherapy
All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis
Paclitaxel and Carboplatin Chemotherapy With Bevacizumab
All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis
| Group | Source count |
|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 337 |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 337 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 10.4 | Not reported | 9.7 | 11.0 | Not reported |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 13.8 | Not reported | 13.0 | 14.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 9.7
- upper Limit
- 11.0
- value
- 10.4
- group Id
- OG001
- lower Limit
- 13.0
- upper Limit
- 14.7
- value
- 13.8
- denoms
- counts
- group Id
- OG000
- value
- 337
- group Id
- OG001
- value
- 337
- units
- Participants
- description
- Progression-free survival was defined as the time from randomization to cancer progression as shown on radiography, according to the RECIST version 1.0 criteria, an increase in the CA125 level according to Gynecologic Cancer InterGroup (GCIG) criteria, global deterioration of health, or death from any cause.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis
- id
- OG000
- title
- Paclitaxel and Carboplatin Chemotherapy
- description
- All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis
- id
- OG001
- title
- Paclitaxel and Carboplatin Chemotherapy With Bevacizumab
- param Type
- MEDIAN
- population Description
- All patients who were enrolled and eligible for the chemotherapy analysis (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).
- reporting Status
- POSTED
- time Frame
- Radiographic assessment of disease was conducted during chemotherapy and then every 6 months during the maintenance / surveillance phase
- title
- Progression-free Survival (Chemotherapy Analysis)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice